ArticlePsychedelic medicine (New Rochelle, N.Y.)2023
A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.
Article in Psychedelic medicine (New Rochelle, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Psilocybin restores behavior and 5-HTCell reports. Medicine · 2026Article
- Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury.Molecular psychiatry · 2026Article
- Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring.Nature communications · 2025Article
- Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.Psychopharmacology · 2025Article
- Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress.Translational psychiatry · 2025Article
- Epigenetic mechanisms of rapid-acting antidepressants.Translational psychiatry · 2024Review
- Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.bioRxiv : the preprint server for biology · 2024Article
- Therapeutic mechanisms of psychedelics and entactogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality.Journal of psychiatry & neuroscience : JPNReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psilocybin has shown long-lasting antidepressant effects in preclinical and clinical trials, but the mechanisms responsible are unclear. As both passive coping strategies and pattern separation deficits are characteristics of major depression, we used adult female rats subjected to adolescent chronic restraint stress (aCRS) to investigate the effects of psilocybin on forced swim test (FST) and object pattern separation (OPS) behaviors 5 weeks after a single administration. Methods: Adolescent rats were randomly assigned to one of four treatment groups-not restrained/saline, not restrained/psilocybin, restrained/saline, and restrained/psilocybin. Restrained group rats were restrained for 1 h daily from day 1 through day 14. Saline and psilocybin were administered on day 21, OPS was evaluated on days 51-55, forced swim behavior was evaluated on day 57 or 58, and animals were sacrificed on day 63. Brains were removed and the medial prefrontal cortex, dorsal dentate gyrus, dorsal CA3 hippocampal area, and ventral hippocampus were microdissected out and prepared for mRNA analysis of a panel of genes relevant to synaptic plasticity using quantitative polymerase chain reaction. Results: Psilocybin rescued cognitive function in aCRS rats in both assays, but did not affect either measure in nonstressed rats. Immobility in the FST was correlated with impaired discrimination ability in the OPS. No differences in mRNA expression for a panel of genes related to structural synaptic proteins were observed between groups, although stress was a significant contributor to variability of the gene for glutamate metabotropic receptor 2 ( Conclusions: Our data indicate that aCRS and OPS represent a powerful system with translational relevance to study depression, and that a single treatment with psilocybin has long-lasting antidepressant-like effects without long-term alterations of mRNA related to synaptic density in brain areas relevant to depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.